Rosetta Genomics (NASDAQ: ROSG) is one of 186 public companies in the “Biotechnology & Medical Research” industry, but how does it contrast to its rivals? We will compare Rosetta Genomics to similar companies based on the strength of its profitability, dividends, valuation, analyst recommendations, institutional ownership, earnings and risk.
This table compares Rosetta Genomics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Rosetta Genomics Competitors||-3,341.99%||-537.73%||-40.09%|
8.3% of Rosetta Genomics shares are held by institutional investors. Comparatively, 49.8% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 14.7% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Rosetta Genomics and its rivals top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Rosetta Genomics||$9.23 million||-$16.23 million||-0.06|
|Rosetta Genomics Competitors||$217.29 million||-$39.39 million||-73.91|
Rosetta Genomics’ rivals have higher revenue, but lower earnings than Rosetta Genomics. Rosetta Genomics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of current recommendations for Rosetta Genomics and its rivals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Rosetta Genomics Competitors||531||2400||6579||123||2.65|
Rosetta Genomics presently has a consensus price target of $3.50, indicating a potential upside of 392.96%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 17.39%. Given Rosetta Genomics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Rosetta Genomics is more favorable than its rivals.
Risk & Volatility
Rosetta Genomics has a beta of 0.31, indicating that its share price is 69% less volatile than the S&P 500. Comparatively, Rosetta Genomics’ rivals have a beta of 1.54, indicating that their average share price is 54% more volatile than the S&P 500.
Rosetta Genomics beats its rivals on 7 of the 12 factors compared.
Rosetta Genomics Company Profile
Rosetta Genomics Ltd. is engaged in developing and commercializing new diagnostic tests based on various genomics markers, including deoxyribonucleic acid (DNA), micro ribonucleic acid (microRNA) and protein biomarkers and using various technologies, including, Quantitative polymerase chain reaction (qPCR), microarrays, Next Generation Sequencing (NGS) and Fluorescence In Situ Hybridization (FISH). It is marketing and selling over four diagnostic tests based on its microRNA technologies, which include RosettaGX Cancer Origin, mi-LUNG, mi-KIDNEY and RosettaGX Reveal. Its therapeutic pipeline consists of the projects, which include Rimonim Consortium and Magneton Project. It focuses on developing diagnostic assay, RosettaGX Reveal V2. It is also focusing on developing Bladder cancer risk stratification. Its PersonalizeDx is focused on the detection of genomic changes through FISH technology, which helps to detect cancer.
Receive News & Ratings for Rosetta Genomics Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rosetta Genomics Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.